ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,924 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentHorgenNumab Therapeutics AG
Numab Therapeutics AG Logo
Verified· 3 sources

Numab Therapeutics AG

Summary

About the company

The core activity of Numab Therapeutics AG is the development and research of immunological and immuno-oncological drugs, in particular multispecific biotherapeutics. The company focuses on the development of next-generation drugs and platforms for the treatment of diseases, specializing in the development of proprietary technologies such as λ-Cap and MATCH.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Pharmaceutical Industry
✓ Offered4
Development of multispecific antibody-based immunotherapies
Development of multispecific antibody-based immunotherapies for inflammation and cancer, using proprietary platforms λ-Cap™ and MATCH™ as well as in-house research and development programs.
Antibody discovery and engineering platform (λ-Cap™ / MATCH™)
Proprietary platform for antibody discovery, stabilization and engineering of mono- and multispecific therapeutics with modular assembly, high stability and a reproducible process.
Pipeline of clinical and preclinical drug programs
Own pipeline with programs in research, preclinical and clinical development for immunology, immuno-oncology, respiratory diseases, CNS and solid tumors.
Partnerships for preclinical and clinical development
Licensing, co-development and collaboration projects with pharma and biotech partners to fund and further develop multispecific antibody programs.
Press

Media

January 9, 2025Media
Numab raises additional CHF50 million
startupticker.ch
May 28, 2024Media
Johnson & Johnson acquires Numab spin-off for USD 1.25 billion
startupticker.ch
Comparisons

Numab Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Numab Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Numab Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Bachtobelstrasse 5
8810 Horgen

At a glance

Legal form
Corporation
UID
CHE-199.155.103
Founded
2016 · 10 years
Last commercial register change
July 20, 2026
Employees
51 to 100

Knowledge

No knowledge articles yet

Once Numab Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

CA
CDR-Life AG
Horgen
MA
Mabylon AG
Schlieren
NS
Neurimmune Subone AG
Schlieren
PA
Philochem AG
Otelfingen
AB
Araris Biotech AG
Au Zh
CR
Charles River Laboratories Switzerland AG
Hettlingen
NA
Neurimmune AG
Schlieren
AA
Athebio AG
Schlieren